- Home
- WNEB vs SLS Comparison
WNEB vs SLS Comparison
Compare WNEB & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- SLS
- Stock Information
- Founded
- WNEB 1853
- SLS 2012
- Country
- WNEB United States
- SLS United States
- Employees
- WNEB N/A
- SLS N/A
- Industry
- WNEB Savings Institutions
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- SLS Health Care
- Exchange
- WNEB Nasdaq
- SLS Nasdaq
- Market Cap
- WNEB 195.7M
- SLS 185.3M
- IPO Year
- WNEB N/A
- SLS N/A
- Fundamental
- Price
- WNEB $12.10
- SLS $1.69
- Analyst Decision
- WNEB Buy
- SLS Strong Buy
- Analyst Count
- WNEB 2
- SLS 1
- Target Price
- WNEB $11.00
- SLS $7.00
- AVG Volume (30 Days)
- WNEB 62.1K
- SLS 2.0M
- Earning Date
- WNEB 10-22-2025
- SLS 11-12-2025
- Dividend Yield
- WNEB 2.31%
- SLS N/A
- EPS Growth
- WNEB N/A
- SLS N/A
- EPS
- WNEB 0.59
- SLS N/A
- Revenue
- WNEB $76,036,000.00
- SLS N/A
- Revenue This Year
- WNEB N/A
- SLS N/A
- Revenue Next Year
- WNEB $7.36
- SLS N/A
- P/E Ratio
- WNEB $20.56
- SLS N/A
- Revenue Growth
- WNEB 2.15
- SLS N/A
- 52 Week Low
- WNEB $7.63
- SLS $0.77
- 52 Week High
- WNEB $12.70
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- WNEB 54.77
- SLS 42.73
- Support Level
- WNEB $11.90
- SLS $1.65
- Resistance Level
- WNEB $12.70
- SLS $2.01
- Average True Range (ATR)
- WNEB 0.22
- SLS 0.11
- MACD
- WNEB -0.10
- SLS -0.02
- Stochastic Oscillator
- WNEB 25.00
- SLS 11.11
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.